Media

Press Releases and Events

Angelini Pharma finalizes the acquisition agreement

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments

Arvelle Announces Partnership with Durbin Across Europe